Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
6.00
-0.01 (-0.17%)
At close: Dec 23, 2025, 4:00 PM EST
5.99
-0.01 (-0.17%)
After-hours: Dec 23, 2025, 5:26 PM EST
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $240.00K in the quarter ending September 30, 2025, a decrease of -89.92%. This brings the company's revenue in the last twelve months to $16.86M, down -78.55% year-over-year. In the year 2024, Vir Biotechnology had annual revenue of $74.21M, down -13.90%.
Revenue (ttm)
$16.86M
Revenue Growth
-78.55%
P/S Ratio
49.16
Revenue / Employee
$41,324
Employees
408
Market Cap
834.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VIR News
- 7 days ago - Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
- 4 weeks ago - Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - Business Wire
- 6 weeks ago - Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile - Business Wire
- 6 weeks ago - Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference - Business Wire
- 6 weeks ago - Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta - Business Wire
- 2 months ago - Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire